跳至主要内容
临床试验/NCT02133950
NCT02133950Unknown不适用

A Single Centre Randomised Controlled Study Into the Segmentation of Preimplantation Genetic Diagnosis (PGD) Treatment by Comparing Cumulative Pregnancy Rates Following Cryopreservation of All Genetically Transferable Embryos After PGD, Compared to Fresh Embryo Transfer Cumulative With Frozen Embryo Transfer of Genetically Transferable Embryos.

Universitair Ziekenhuis Brussel2 个研究点 分布在 1 个国家目标入组 252 人开始时间: 2014年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
252
试验地点
2
主要终点
cumulative live birth rate of a single PGD treatment

研究概览

简要总结

A single centre observational study into the segmentation of preimplantation genetic diagnosis (PGD) treatment by comparing cumulative pregnancy rates following cryopreservation of all genetically transferable embryos after PGD, compared to fresh embryo transfer cumulative with frozen embryo transfer of genetically transferable embryos.The primary aim of the study is to assess the feasibility and effectiveness of segmentation in terms of pregnancy rates. The secondary aim is to assess the logistic advantage of segmentation in PGD cycles.

Experimental questions

  1. Is the cumulative live birth rate rate of a single PGD treatment when all genetically transferable embryos are cryopreserved by vitrification prior to consecutive in utero transfer in unstimulated cycles, superior to PGD treatment with fresh embryo transfer cumulative with transfer of supernumerary cryopreserved embryos?
  2. Does the technique of segmentation allow better planning of DNA amplification and genetic analysis?

Design The proposed design is a pragmatic, prospective randomised controlled trial

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 1st, 2nd or 3rd cycle of PGD in which embryo transfer was performed
  • Indications for PGD: monogenic indications and X-linked disorders with a 25-50% risk of transmission and that are not associated with reduced ovarian response
  • Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation.
  • Regular menstrual cycles of 21-35 days, presumed to be ovulatory.

排除标准

  • POLYCYSTIC OVARIAN SYNDROME (Rotterdam criteria *)
  • * At least two of the following three features: (i) Oligo- and/or anovulation (ii) Clinical and/or biochemical signs of hyperandrogenism (iii) Polycystic ovaries and exclusion of other aetiologies (congenital adrenal hyperplasias, androgen-secreting tumours, Cushing's syndrome)
  • Poor responders (Bologna criteria **)
  • * * At least two of the following three features: (i) Advanced maternal age (≥40 years) or any other risk factor for poor ovarian response (POR); (ii) A previous POR (≤3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian reserve test (i.e. antral follicle count (AFC) 5-7 follicles, or anti-Mullerian hormone (AMH) 0.5-1.1 ng/ml).
  • Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)
  • anticipated high response: AMH >5.0 ng/ml or AFC >20
  • Endometriosis ≥ grade 3
  • Age > 40 years and 364 days

结局指标

主要结局

cumulative live birth rate of a single PGD treatment

时间窗: 1 year

cumulative LBR

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

VERPOEST WILLEM

professor dr

Universitair Ziekenhuis Brussel

研究点 (2)

Loading locations...

相似试验